Osteoarthritis Resource Center

Arthritis Rate ID'd After Posterior Shoulder Stabilization

Arthritis Rate ID’d After Posterior Shoulder Stabilization

Among active-duty service members with posterior shoulder instability requiring surgical fixation, 12.7 percent develop glenohumeral arthritis, according to a study presented at the combined...
Cognitive Decline Ups Bone Fracture Risk, and More

Rheumatology Round-up: Six-Year Outcomes of ACL Revision Surgery; and More

RA Predictors ID'd in Undifferentiated Large Joint Arthritis Autoantibody positivity and subclinical synovitis are independent predictors of rheumatoid arthritis (RA) among patients presenting with undifferentiated...

Older AFib Patients with Diabetes and Osteoarthritis at Higher Risk of Cardiovascular Diseases

A new study shows that among older adults with non-valvular atrial fibrillation (NVAF), those with diabetes mellitus (DM) and osteoarthritis (OA) incur a higher...
therapies, tocilizumab, rheum, RA, keenan, autoimmune, tofacitinib, telemedicine, covid-19, Hydroxychloroquine, Secukinumab, interview, rheumatologists, rheumatologist, arthroplasty, arthritis, rheumatic, ixekizumab, RA, rheumatoid, FDA, Rheum Round-up: Five RA Drugs Compared, Two THA Approaches, and more

Rheum Round-up: CEO of Flexion Therapeutics on Developing MSK Therapies, Risk Factors for Radiographic...

DocWire News with spoke with Mike Clayman, MD, CEO at Flexion Therapeutics, a company focused on the development of novel, local therapies for the...
Researchers Identify Risk Factors for Radiographic Progression of Osteoarthritis of the Knee

Researchers Identify Risk Factors for Radiographic Progression of Osteoarthritis of the Knee

Patients with mild radiographic osteoarthritis (OA) of the knee who use non-steroidal anti-inflammatory drugs (NSAIDs) and do not meet physical activity guidelines are at...
video

Dr. Mike Clayman, CEO of Flexion Therapeutics, on Developing New Therapies for Musculoskeletal Disorders

DocWire News with spoke with Mike Clayman, M.D., CEO at Flexion Therapeutics, a company focused on the development of novel, local therapies for the...
Could Patients’ Expectations Impact Clinical Response to DMARDs in Rheumatoid Arthritis?

Could Patients’ Expectations Impact Clinical Response to DMARDs in Rheumatoid Arthritis?

A study observed a correlation between patients’ expectations toward newly induced disease-modifying antirheumatic drug (DMARD) therapies and clinical response among patients with rheumatoid arthritis...

Curated Journal Reading List